← Eichor
Study identifier: NCT06442267 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support

Condition: Respiratory Insufficiency · Circulatory Failure · Thromboembolism  ·  Sponsor: Medical University of Vienna

PhasePhase 4
Planned participants90
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy in comparison to the current standard, unfractionated heparin, as measured by the incidence of thromboembolic events during the duration of ECMO therapy

This description comes directly from the study's public registry record.

Talk to the study team

Vincenz Scharner, MD  ·  +43 1 40400  ·  vincenz.scharner@meduniwien.ac.at

Always discuss trial participation with your own doctor first.

Locations (1)

Medical University of ViennaVienna, State of Vienna, AustriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06442267